Europe Wound Biologics Market - Focused Insights 2023-2028

The Europe wound biologics market was valued at USD 420.00 million in 2022 and is expected to reach USD 710.02 million by 2028, growing at a CAGR of 9.14% during the forecast period. Constant development and launch of innovative products are important for vendors operating in a highly competitive market like Europe to achieve healthy sales growth and increase market share. Moreover, the increasing adoption of advanced technologies in Wound Biologics is a primary trend in the global Wound biologics market. A significant number of research and development activities have been conducted in wound management.

This report offers market size & forecast data for the wound biologics market in Europe. The revenue generated from the sale of wound biologics products is included in the report. This report provides a comprehensive and current market scenario of the European wound biologics market, including market size, anticipated market forecast, relevant market segmentations, and industry trends. The study considers a detailed scenario of the present wound biologics market and its market dynamics for 2023−2028 in Europe. It covers a detailed overview of several market growth enablers, restraints, and trends.

The major market players are investing more in their R&D. This is creating lucrative opportunities for the growth of the European wound biologics market. For example, Convatec launched Innovamatrix in wound biologics treatment. The innovations in the field of cell and gene therapies are paving the way for a positive shift in the wound biologics market growth. The report offers both the demand and supply aspects of the market and profiles and examines leading companies and other prominent players operating in the market.

The products that are derived from living organisms or cells for treating wounds are called wound biologics. These are intended to facilitate the re-establishment of innate repair mechanisms.

Key Highlight:

• The demand for wound biologics is on the rise in the market due to multiple factors, including an increasing geriatric population, growing consumer awareness regarding usage, high prevalence of chronic and acute wounds, and increasing adoption of wound biologics.
• The specialty wound clinic end-user segment accounted for the highest share of the Europe wound biologics market in 2022. An increasing number of diabetic people in Europe is one of the major factors that is increasing the number of people visiting specialty care clinics for the Wound.
• The Europe wound biologics market by product is segmented into biological skin substitutes and growth factors. The biological skin substitutes segment accounted for the highest share of the market in 2022 and is projected to grow at the highest CAGR during the forecast period. The increasing demand for biological skin substitutes is due to the rising number of diabetic wounds, increased preference for wound biologics, and rise in the geriatric population.
• The chronic wound type segment dominated the Europe wound biologics market in 2022. The higher segmental share is mainly due to factors such as increasing cases of diabetes, obesity, and increased age that contribute to the rise in the number of chronic wound cases.
• Factors such as technological & material advancements, introduction of new products, well-developed healthcare infrastructure, extensive research & development activities, presence of leading key vendors, and government support also contribute to the growth of the Europe wound biologics market.